- Home
- SKT vs APLS Comparison
SKT vs APLS Comparison
Compare SKT & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKT
- APLS
- Stock Information
- Founded
- SKT 1981
- APLS 2009
- Country
- SKT United States
- APLS United States
- Employees
- SKT N/A
- APLS N/A
- Industry
- SKT Real Estate Investment Trusts
- APLS Biotechnology: Pharmaceutical Preparations
- Sector
- SKT Real Estate
- APLS Health Care
- Exchange
- SKT Nasdaq
- APLS Nasdaq
- Market Cap
- SKT 3.7B
- APLS 4.0B
- IPO Year
- SKT 1993
- APLS 2017
- Fundamental
- Price
- SKT $33.13
- APLS $30.13
- Analyst Decision
- SKT Buy
- APLS Buy
- Analyst Count
- SKT 8
- APLS 18
- Target Price
- SKT $35.00
- APLS $46.71
- AVG Volume (30 Days)
- SKT 698.5K
- APLS 2.1M
- Earning Date
- SKT 02-19-2025
- APLS 02-25-2025
- Dividend Yield
- SKT 3.35%
- APLS N/A
- EPS Growth
- SKT 1.00
- APLS N/A
- EPS
- SKT 0.87
- APLS N/A
- Revenue
- SKT $522,818,000.00
- APLS $715,216,000.00
- Revenue This Year
- SKT N/A
- APLS $95.82
- Revenue Next Year
- SKT $4.34
- APLS $12.02
- P/E Ratio
- SKT $38.14
- APLS N/A
- Revenue Growth
- SKT 13.36
- APLS 162.10
- 52 Week Low
- SKT $25.67
- APLS $24.34
- 52 Week High
- SKT $37.57
- APLS $71.90
- Technical
- Relative Strength Index (RSI)
- SKT 38.84
- APLS 44.83
- Support Level
- SKT $32.74
- APLS $27.61
- Resistance Level
- SKT $33.99
- APLS $30.13
- Average True Range (ATR)
- SKT 0.65
- APLS 1.50
- MACD
- SKT -0.01
- APLS -0.35
- Stochastic Oscillator
- SKT 44.02
- APLS 33.82
About SKT Tanger Inc.
Tanger Inc is a leading owner and operator of outlet and open-air retail shopping destinations. Tanger's portfolio of 38 outlet centers and one open-air lifestyle center comprises over 15 million square feet well positioned across tourist destinations and vibrant markets in U.S. states and Canada.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.